This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...
The early stage company is developing a new approach to gene editing to treat rare genetic diseases. It does this using mRNA, ...
New study reveals that TLE6 protein deficiency causes male infertility in mice. These findings suggest potential genetic ...
In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...
Fintel reports that on January 27, 2025, Morgan Stanley downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 449.14% ...
Colossal Biosciences is now valued at over $10 billion and is working on ambitious projects to resurrect multiple long ...
CRISPR-Cas systems have been exploited for targeted genome editing ... self-limiting suppression was achieved. Applying the CRISPR-Cas9 system to edit high GC content genomes has been challenging ...
Colossal Biosciences is working to bring back species like the woolly mammoth using CRISPR-Cas9 technology. The project aims to restore lost biodivers ...
Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.
By using genetic material from two male mice, researchers successfully created pups that survived to adulthood, offering ...
This is a useful study that seeks to address the role of the TET family of DNA demethylation enzymes in pancreatic beta cell senescence in the context of type 2 diabetes (T2DM). Although the concepts ...
In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...